Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel Free NMRA Stock Alerts

Neumora Therapeutics (NMRA) Competitors

Neumora Therapeutics logo
$2.30 -0.01 (-0.43%)
Closing price 04:00 PM Eastern
Extended Trading
$2.27 -0.03 (-1.30%)
As of 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NMRA vs. AMLX, SION, NRIX, NBTX, and ARDX

Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Amylyx Pharmaceuticals (AMLX), Sionna Therapeutics (SION), Nurix Therapeutics (NRIX), Nanobiotix (NBTX), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.

How does Neumora Therapeutics compare to Amylyx Pharmaceuticals?

Neumora Therapeutics (NASDAQ:NMRA) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Neumora Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 233.33%. Amylyx Pharmaceuticals has a consensus price target of $21.56, indicating a potential upside of 31.20%. Given Neumora Therapeutics' higher possible upside, equities analysts plainly believe Neumora Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neumora Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.56
Amylyx Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.86

Neumora Therapeutics has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500.

Amylyx Pharmaceuticals has higher revenue and earnings than Neumora Therapeutics. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neumora TherapeuticsN/AN/A-$236.93M-$1.45N/A
Amylyx Pharmaceuticals$87.37M20.89-$144.74M-$1.55N/A

Amylyx Pharmaceuticals' return on equity of -57.52% beat Neumora Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neumora TherapeuticsN/A -146.41% -111.57%
Amylyx Pharmaceuticals N/A -57.52%-52.17%

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 3 mentions for Amylyx Pharmaceuticals and 1 mentions for Neumora Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.66 beat Neumora Therapeutics' score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neumora Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amylyx Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Amylyx Pharmaceuticals beats Neumora Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Sionna Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, Sionna Therapeutics had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 3 mentions for Sionna Therapeutics and 1 mentions for Neumora Therapeutics. Sionna Therapeutics' average media sentiment score of 1.11 beat Neumora Therapeutics' score of 0.00 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neumora Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sionna Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

47.7% of Neumora Therapeutics shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 3.9% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neumora Therapeutics has a beta of 3.02, meaning that its stock price is 202% more volatile than the S&P 500. Comparatively, Sionna Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.

Neumora Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 233.33%. Sionna Therapeutics has a consensus target price of $53.00, indicating a potential upside of 29.36%. Given Neumora Therapeutics' higher possible upside, research analysts plainly believe Neumora Therapeutics is more favorable than Sionna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neumora Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.56
Sionna Therapeutics
2 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.82

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neumora TherapeuticsN/AN/A-$236.93M-$1.45N/A
Sionna TherapeuticsN/AN/A-$75.27M-$1.95N/A

Sionna Therapeutics' return on equity of -22.87% beat Neumora Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neumora TherapeuticsN/A -146.41% -111.57%
Sionna Therapeutics N/A -22.87%-21.71%

Summary

Sionna Therapeutics beats Neumora Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Neumora Therapeutics compare to Nurix Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, Nurix Therapeutics had 9 more articles in the media than Neumora Therapeutics. MarketBeat recorded 10 mentions for Nurix Therapeutics and 1 mentions for Neumora Therapeutics. Nurix Therapeutics' average media sentiment score of 0.70 beat Neumora Therapeutics' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neumora Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nurix Therapeutics
6 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

47.7% of Neumora Therapeutics shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neumora Therapeutics has a beta of 3.02, meaning that its stock price is 202% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.

Neumora Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 233.33%. Nurix Therapeutics has a consensus target price of $30.46, indicating a potential upside of 83.50%. Given Neumora Therapeutics' higher possible upside, research analysts plainly believe Neumora Therapeutics is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neumora Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.56
Nurix Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

Neumora Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neumora TherapeuticsN/AN/A-$236.93M-$1.45N/A
Nurix Therapeutics$83.98M20.44-$264.46M-$3.16N/A

Neumora Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Nurix Therapeutics' return on equity of -64.21% beat Neumora Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neumora TherapeuticsN/A -146.41% -111.57%
Nurix Therapeutics -411.37%-64.21%-48.44%

Summary

Neumora Therapeutics beats Nurix Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nanobiotix presently has a consensus target price of $26.67, indicating a potential downside of 23.31%. Neumora Therapeutics has a consensus target price of $7.67, indicating a potential upside of 233.33%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Nanobiotix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanobiotix
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Neumora Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.56

Nanobiotix's return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NanobiotixN/A N/A N/A
Neumora Therapeutics N/A -146.41%-111.57%

In the previous week, Nanobiotix had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 3 mentions for Nanobiotix and 1 mentions for Neumora Therapeutics. Nanobiotix's average media sentiment score of 0.75 beat Neumora Therapeutics' score of 0.00 indicating that Nanobiotix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nanobiotix
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neumora Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Nanobiotix has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the S&P 500.

Nanobiotix has higher revenue and earnings than Neumora Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nanobiotix$36.87M45.76-$27.11MN/AN/A
Neumora TherapeuticsN/AN/A-$236.93M-$1.45N/A

Summary

Neumora Therapeutics beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

How does Neumora Therapeutics compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Ardelyx presently has a consensus target price of $15.70, suggesting a potential upside of 120.20%. Neumora Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 233.33%. Given Neumora Therapeutics' higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Ardelyx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ardelyx
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90
Neumora Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.56

Neumora Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Neumora Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ardelyx-13.58% -38.11% -11.85%
Neumora Therapeutics N/A -146.41%-111.57%

In the previous week, Ardelyx had 22 more articles in the media than Neumora Therapeutics. MarketBeat recorded 23 mentions for Ardelyx and 1 mentions for Neumora Therapeutics. Ardelyx's average media sentiment score of 0.28 beat Neumora Therapeutics' score of 0.00 indicating that Ardelyx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ardelyx
6 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Neumora Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ardelyx has higher revenue and earnings than Neumora Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$407.32M4.32-$61.60M-$0.23N/A
Neumora TherapeuticsN/AN/A-$236.93M-$1.45N/A

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 4.8% of Ardelyx shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ardelyx has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500.

Summary

Ardelyx beats Neumora Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMRA vs. The Competition

Export
MetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$422.01M$3.40B$6.25B$11.77B
Dividend YieldN/A2.23%2.74%5.26%
P/E Ratio-1.5938.5729.2527.07
Price / SalesN/A280.02504.6873.47
Price / CashN/A125.0643.3053.90
Price / Book3.717.059.676.69
Net Income-$236.93M$23.62M$3.55B$332.64M
7 Day Performance2.22%3.67%1.70%2.01%
1 Month Performance15.00%7.17%5.62%9.19%
1 Year Performance229.70%67.04%34.42%39.59%

Neumora Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMRA
Neumora Therapeutics
3.0405 of 5 stars		$2.30
-0.4%		$7.67
+233.3%		N/A$422.01MN/AN/A108
AMLX
Amylyx Pharmaceuticals
2.4817 of 5 stars		$16.46
+2.8%		$21.56
+31.0%		N/A$1.78B$87.37MN/A200
SION
Sionna Therapeutics
2.5771 of 5 stars		$40.45
+3.3%		$53.00
+31.0%		N/A$1.77BN/AN/A35
NRIX
Nurix Therapeutics
2.68 of 5 stars		$16.93
+0.7%		$30.46
+79.9%		N/A$1.74B$83.98MN/A300
NBTX
Nanobiotix
1.7176 of 5 stars		$31.16
-11.3%		$26.67
-14.4%		N/A$1.70B$36.87MN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NMRA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel